- Home
- LNG vs XGN Comparison
LNG vs XGN Comparison
Compare LNG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNG | XGN |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7B | 64.5M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LNG | XGN |
|---|---|---|
| Price | $275.08 | $3.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $292.81 | $9.14 |
| AVG Volume (30 Days) | ★ 3.7M | 243.0K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 69.93 | N/A |
| EPS | ★ 24.13 | N/A |
| Revenue | ★ $19,976,000,000.00 | N/A |
| Revenue This Year | $16.51 | $8.06 |
| Revenue Next Year | $5.50 | $12.93 |
| P/E Ratio | $11.75 | ★ N/A |
| Revenue Growth | ★ 27.21 | N/A |
| 52 Week Low | $186.20 | $2.59 |
| 52 Week High | $300.94 | $12.23 |
Technical Indicators
Market Signals| Indicator | LNG | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 48.30 |
| Support Level | $220.98 | $2.59 |
| Resistance Level | $300.22 | $3.79 |
| Average True Range (ATR) | 11.32 | 0.21 |
| MACD | -2.44 | 0.07 |
| Stochastic Oscillator | 36.64 | 75.00 |
Price Performance
Historical ComparisonAbout LNG Cheniere Energy Inc.
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.